Skip to main content

Table 4 Mean Migraine-Specific Questionnaire (MSQ) and Medical Outcome Study Short Form 36 (SF-36) scores at baseline for pooled intent-to-treat (ITT) subjects with < 50% and ≥ 50% reductions in monthly migraine frequency, regardless of study medication*

From: The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials

  < 50% Responders ≥ 50% Responders
MSQ Domain n Baseline n Baseline
Emotional Function 455 55.5 244 55.2
Role Prevention 454 68.3 243 67.0
Role Restriction 455 50.1 244 49.4
SF-36 Subscale n Baseline n Baseline
Physical Functioning 454 83.1 243 80.3
Bodily Pain 453 51.4 244 51.6
Vitality 454 51.7 243 50.0
General Health 447 68.4 242 68.3
Role-Emotional 453 71.0 240 68.2
Role Physical 452 44.6 241 44.1
Mental Health 454 71.3 243 70.7
Social Functioning 455 69.8 244 68.6
Physical Component Score 439 43.2 237 42.8
Mental Component Score 439 47.4 237 46.9
  1. *N values reflect the numbers of patients with evaluable data on each domain, not the ITT population.